register

News & Trends - MedTech & Diagnostics

Innovative method to regenerate articular cartilage for patient surgery

Health Industry Hub | June 29, 2020 |

MedTech News: Recipient of the Royal Australasian College of Surgeons (RACS) Senior Lecturer Fellowship, Associate Professor Claudia Di Bella, and her research team at BioFab3D, trademarked a ground-breaking method of stem cell transplantation.

BioFab3D is Australia’s first robotics and biomedical engineering centre within a hospital. Researchers, clinicians, engineers and industry partners work to build biological structures such as cartilage, muscle, bone, nerves and organs – almost anything that requires repair through disease and physical trauma.

St Vincent’s Hospital Melbourne has partnered with four universities – the University of Melbourne, RMIT University, Swinburne University of Technology and University of Wollongong – to create a unique hub for
innovation and translation.

Associate Professor Di Bella’s team is regenerating articular cartilage by using advanced biofabrication techniques and technology with the use of stem cells that are printed within a gelatinous scaffold and then cultured in 3D. The cartilage project is the largest program at BioFab3D.

The typical pathway for a stem cell transplant procedure involves taking
cells from the patient, then printing and growing them in the lab while the patient waits at home for the cells to do their work and create tissue. The third and final stage is reimplantation into the patient.

The BioFab3D team is hoping to eliminate the second stage of this process because it’s a big obstacle to Therapeutic Goods Administration (TGA) approval, or to any process that involves tissue engineering.

The revolutionary new procedure that the team hopes to implement will require one simple step. It will take the patient’s own stem cells, then mix them with a scaffold so they have somewhere to grow before putting them back into the same patient to regenerate their own cartilage.

The product has been trademarked, registered and seeking a pathway towards commercialisation. A clinical trial will also commence shortly.


News & Trends - Pharmaceuticals

Will the new PBS campaign pressure the government to act?

Will the new PBS campaign pressure the government to act?

Health Industry Hub | September 18, 2024 |

Pharma News: The medicines industry is ramping up its campaign to slash delays in patient access to new and innovative […]

More


News & Trends - MedTech & Diagnostics

Private hospitals struggle despite surge in admissions: Financial crisis worsens as inflation outpaces benefits

Private hospitals struggle despite surge in admissions: Financial crisis worsens as inflation outpaces benefits

Health Industry Hub | September 18, 2024 |

MedTech & Diagnostics News: Private hospital admissions are on the rise, but this uptick is not enough to counter the […]

More


Digital & Innovation

Health sector and government under scrutiny: Record data breaches expose millions

Health sector and government under scrutiny: Record data breaches expose millions

Health Industry Hub | September 18, 2024 |

Digital & Innovation: The national privacy regulator has raised alarm over escalating threats, reporting a record surge in data breach notifications. […]

More


Medical and Science

Diabetes research funding plummets by 35%: Consultation launched to reverse decline

Diabetes research funding plummets by 35%: Consultation launched to reverse decline

Health Industry Hub | September 18, 2024 |

Medical & Science: Australia’s diabetes crisis is deepening, with calls for urgent action growing louder. The Standing Committee on Health, […]

More


This content is copyright protected. Please subscribe to gain access.